Florbetaben as an Amyloid Plaque Marker in Elderly Patients With Focal or Disseminated Superficial Hemosiderosis (FBB ACC)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02664571 |
Recruitment Status :
Withdrawn
(experimental drug prohibited by the ANSM (French competent authority))
First Posted : January 27, 2016
Last Update Posted : January 25, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Amyloid Cerebral Angiopathy Alzheimer Disease | Device: Pet scan with FBB Device: MRI scan Biological: APO E genotyping | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 0 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Investigator, Outcomes Assessor) |
Primary Purpose: | Diagnostic |
Official Title: | Evaluation of Florbetaben as an Amyloid Plaque Marker in Elderly Patients With Focal or Disseminated Superficial Hemosiderosis |
Estimated Study Start Date : | July 2020 |
Estimated Primary Completion Date : | July 2021 |
Estimated Study Completion Date : | July 2021 |

Arm | Intervention/treatment |
---|---|
ACA with isolated hemosiderosis
This group is composed of patients with amyloid cerebral angiopathy (ACA) with isolated hemosiderosis. Intervention: Pet scan with FBB Intervention: MRI scan Intervention: APO E genotyping |
Device: Pet scan with FBB
Patients will have a pet scan with Florbetaben (NEURACEQ : FBB). All other care corresponds to routine care. Florbetaben is used during pet scans to visualize beta amyloid plaques and cannot be a separate intervention in and of itself. Device: MRI scan Subjects will have an MRI scan at inclusion. Biological: APO E genotyping Subjects will have APO (apolipoprotein) E genotyping if not already known. |
ACA with lobar hematoma(s)
This group is composed of patients with amyloid cerebral angiopathy (ACA) with lobar hematoma(s). Intervention: Pet scan with FBB Intervention: MRI scan Intervention: APO E genotyping |
Device: Pet scan with FBB
Patients will have a pet scan with Florbetaben (NEURACEQ : FBB). All other care corresponds to routine care. Florbetaben is used during pet scans to visualize beta amyloid plaques and cannot be a separate intervention in and of itself. Device: MRI scan Subjects will have an MRI scan at inclusion. Biological: APO E genotyping Subjects will have APO (apolipoprotein) E genotyping if not already known. |
Alzheimer's without ACA
This group is composed of Alzheimer's type dementia without MRI signs in favor of amyloid cerebral angiopathy (ACA). Intervention: Pet scan with FBB Intervention: MRI scan Intervention: APO E genotyping |
Device: Pet scan with FBB
Patients will have a pet scan with Florbetaben (NEURACEQ : FBB). All other care corresponds to routine care. Florbetaben is used during pet scans to visualize beta amyloid plaques and cannot be a separate intervention in and of itself. Device: MRI scan Subjects will have an MRI scan at inclusion. Biological: APO E genotyping Subjects will have APO (apolipoprotein) E genotyping if not already known. |
Healthy volunteers
This group is composed of healthy volunteers. Intervention: Pet scan with FBB Intervention: MRI scan Intervention: APO E genotyping |
Device: Pet scan with FBB
Patients will have a pet scan with Florbetaben (NEURACEQ : FBB). All other care corresponds to routine care. Florbetaben is used during pet scans to visualize beta amyloid plaques and cannot be a separate intervention in and of itself. Device: MRI scan Subjects will have an MRI scan at inclusion. Biological: APO E genotyping Subjects will have APO (apolipoprotein) E genotyping if not already known. |
- PET scan with Florbetaben: Standardized Uptake Value Ratio [ Time Frame: Day 0 ]
- On the reference MRI: the number of lobar hemorrhages [ Time Frame: Day 0 ]
- On the reference MRI: the locations of lobar hemorrhages [ Time Frame: Day 0 ]Location is defined as choices from among the following: frontal-right; frontal-left; parietal-right; parietal-left; occipital-right; occipital-left; temporal-right; temporal-left.
- On the reference MRI: The presence/absence classification for superficial siderosis [ Time Frame: Day 0 ]The classification corresponds to one of the following: absence; focal (involving < 4 sulci); disseminated (involving 4 or more sulci).
- On the reference MRI: the locations of superficial siderosis [ Time Frame: Day 0 ]Location is defined as choices from among the following: frontal-right; frontal-left; parietal-right; parietal-left; occipital-right; occipital-left; temporal-right; temporal-left.
- On the reference MRI: the absolute quantitative count of microbleeds [ Time Frame: Day 0 ]
- On the reference MRI: microbleed count category [ Time Frame: Day 0 ]The microbleed count category corresponds to one of the following: 0, 1, 2-4, >4.
- On the reference MRI: The predominant location of microbleeds [ Time Frame: Day 0 ]
- On the reference MRI: a measure of leukoencephalopathy using the ARWMC scale [ Time Frame: Day 0 ]The age-related white matter changes (ARWMC) rating scale rating only the supratentorial white matter for each frontal, parieto-occipital, and temporal localisation: 0 for no lesions, 1 for focal lesions, 2 for beginning confluence of lesions, and 3 for diffuse involvement of the entire region
- Apolipoprotein E genotype [ Time Frame: Day 0 ]Everyone has two copies of the gene so the resulting combination determines your APOE "genotype" as one of the following: E2/E2, E2/E3, E2/E4, E3/E3, E3/E4, or E4/E4.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 60 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria for patients with amyloid cerebral angiopathy with isolated hemosiderosis:
- The patient must have given his/her informed and signed consent
- The patient must be insured or beneficiary of a health insurance plan
- The patient has a single or multiple focal spontaneous hemosiderosis objectified by an MRI
- The patient is does not have dementia (Mini Mental State score> 27)
Inclusion Criteria for patients with amyloid cerebral angiopathy with with lobar hematoma(s):
- The patient must have given his/her informed and signed consent
- The patient must be insured or beneficiary of a health insurance plan
- The patient has one or more spontaneous lobar hematomas with or without hemosiderosis objectified by an MRI
- The patient is does not have dementia (Mini Mental State score> 27)
Inclusion Criteria for patients with Alzheimer's type dementia without MRI signs in favor of amyloid cerebral angiopathy:
- The patient must have given his/her informed and signed consent
- The patient must be insured or beneficiary of a health insurance plan
- The patient has Alzheimer's dementia (Mini Mental State score <24) without hemosiderosis or previous lobar hematoma or history of other brain lesion seen on MRI
Inclusion Criteria for health volunteers:
- The subject must have given his/her informed and signed consent
- The subject must be insured or beneficiary of a health insurance plan
- Healthy volunteers without cerebral neurological history and with normal MRI
- The subject is does not have dementia (Mini Mental State score> 27)
Exclusion Criteria for patients with amyloid cerebral angiopathy with isolated hemosiderosis:
- The patient is participating in another interventional study
- The patient is in an exclusion period determined by a previous study
- The patient is under judicial protection
- The subject (next of kin or legal representative) refuses to sign the consent
- It is not possible to give the subject or his/her representative informed information
- The patient has an contra-indication for performing an MRI
- The patient is in the acute phase (the tracer does not bind in cases of large hematoma)
Exclusion Criteria for patients with amyloid cerebral angiopathy with with lobar hematoma(s):
- The patient is participating in another interventional study
- The patient is in an exclusion period determined by a previous study
- The patient is under judicial protection
- The subject (next of kin or legal representative) refuses to sign the consent
- It is not possible to give the subject or his/her representative informed information
- The patient has an contra-indication for performing an MRI
- The patient is in the acute phase (the tracer does not bind in cases of large hematoma)
Exclusion Criteria fpr patients with Alzheimer's type dementia without MRI signs in favor of amyloid cerebral angiopathy:
- The patient is participating in another interventional study
- The patient is in an exclusion period determined by a previous study
- The patient is under judicial protection
- The subject (next of kin or legal representative) refuses to sign the consent
- It is not possible to give the subject or his/her representative informed information
- The patient has an contra-indication for performing an MRI
- The patient is in the acute phase (the tracer does not bind in cases of large hematoma)
- Haemosiderosis or history of lobar hematoma or other visible cerebral history on MRI
Exclusion Criteria for healthy volunteers:
- The subject is participating in another interventional study
- The subject is in an exclusion period determined by a previous study
- The subject is under judicial protection
- The subject (next of kin or legal representative) refuses to sign the consent
- It is not possible to give the subject or his/her representative informed information
- The subject has an contra-indication for performing an MRI
- Abnormal MRI
The groups will be matched according to sex and age (by increments of 5 years) to the extent possible. Because amyloid cerebral angiopathy is a very rare condition, matching the two factors may be difficult to achieve. We therefore anticipate where appropriate to focus matching on age.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02664571
France | |
CHRU de Nîmes - Hôpital Universitaire Carémeau | |
Nîmes Cedex 09, France, 30029 | |
CH de Perpignan - Hôpital Saint Jean | |
Perpignan, France, 66046 |
Study Director: | Dimitri Renard, MD | Centre Hospitalier Universitaire de Nîmes |
Responsible Party: | Centre Hospitalier Universitaire de Nīmes |
ClinicalTrials.gov Identifier: | NCT02664571 |
Other Study ID Numbers: |
LOCAL/2015/DM-01 2015-004583-11 ( EudraCT Number ) |
First Posted: | January 27, 2016 Key Record Dates |
Last Update Posted: | January 25, 2021 |
Last Verified: | January 2021 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Alzheimer Disease Amyloidosis Hemosiderosis Plaque, Amyloid Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Tauopathies |
Neurodegenerative Diseases Neurocognitive Disorders Mental Disorders Proteostasis Deficiencies Metabolic Diseases Iron Overload Iron Metabolism Disorders Pathological Conditions, Anatomical |